Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.

Address: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Département d'Innovation Thérapeutique et des Essais Précoces, Gustave Roussy, Villejuif, France.; Translational Oncology/Early Clinical Trial Unit, Bavarian Cancer Research Center, National Center for Tumor Diseases, Comprehensive Cancer Center Mainfranken and University Hospital Wurzburg, Wurzburg, Germany.; Department of Medical Oncology, Providence-Swedish Cancer Institute, Seattle, Washington, USA.; Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.; New York Cancer and Blood Specialists, New York, New York, USA.; The Ohio State Health Network, The Ohio State University, Columbus, Ohio, USA.; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Duke Cancer Institute, Duke University, Durham, North Carolina, USA.; Henry Ford Cancer Institute, Detroit, Michigan, USA.; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Medicine, University of Barcelona, Hospital Clinic and IDIBAPS, Barcelona, Spain.; Department of Medical Oncology, New York University Langone Health Perlmutter Cancer Center and Grossman School of Medicine, New York, New York, USA.; Baptist Cancer Center, Memphis, Tennessee, USA.; Amgen Inc., Thousand Oaks, California, USA.; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, Maryland, USA.